(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3R)-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-lcarbamoyl)-3-p-tolyl-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835319

PubChem CID: 56680416

Max Phase: Preclinical

Molecular Formula: C32H45N5O10

Molecular Weight: 659.74

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CC[C@H](c2ccc(C)cc2)[C@H]1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI: InChI=1S/C32H45N5O10/c1-15(2)25(33-18(6)38)29(43)34-21(13-23(39)40)28(42)36-26(16(3)4)31(45)37-12-11-20(19-9-7-17(5)8-10-19)27(37)30(44)35-22-14-24(41)47-32(22)46/h7-10,15-16,20-22,25-27,32,46H,11-14H2,1-6H3,(H,33,38)(H,34,43)(H,35,44)(H,36,42)(H,39,40)/t20-,21+,22+,25+,26+,27+,32?/m1/s1

Standard InChI Key: HNEHYSOLMVADTO-JUVLKVNISA-N

Molfile:

     RDKit          2D

 47 49  0  0  0  0  0  0  0  0999 V2000
   30.4694  -16.7436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7474  -18.9583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0737  -19.4345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3179  -20.2235    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.1440  -20.2374    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.4083  -19.4547    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.6218  -20.9100    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.2963  -19.1711    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.7635  -18.1337    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.0111  -17.7899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.3501  -16.4772    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.0155  -16.9649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.6862  -16.4843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.4341  -15.6960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6100  -15.6954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2081  -16.4772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9198  -16.0647    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.4923  -16.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2081  -17.3022    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.6357  -16.4772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3516  -16.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6357  -17.3022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9198  -17.7147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3516  -17.7147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0633  -16.4772    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.3516  -15.2397    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.7791  -16.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.4950  -16.4772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7791  -15.2397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.4950  -17.3022    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.4950  -14.8272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.2117  -15.2408    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.4958  -14.0033    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.2067  -16.0647    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.9226  -16.4772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6343  -16.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.9226  -17.3022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.2067  -17.7147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6343  -17.7147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6343  -15.2397    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.3158  -18.2339    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.6308  -17.5518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.4132  -17.8112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.0303  -17.2624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.8598  -16.4508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0777  -16.1952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.8138  -17.5206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  6  1  0
  5  7  2  0
  3  8  1  0
  2  9  1  1
 10  9  1  0
 11 12  1  0
  2  3  1  0
  3  4  1  0
 16 17  1  0
 16 18  1  0
 16 19  2  0
 17 20  1  0
 20 21  1  0
 20 22  1  6
 22 23  1  0
 22 24  1  0
 21 25  1  0
 21 26  2  0
 25 27  1  0
 27 28  1  0
 27 29  1  1
 28 30  2  0
 29 31  1  0
 31 32  1  0
 31 33  2  0
 28 34  1  0
 34 35  1  0
 35 36  1  0
 35 37  1  6
 37 38  1  0
 37 39  1  0
 36 11  1  0
 36 40  2  0
  4  5  1  0
 10 41  2  0
 13  1  1  6
  5  6  1  0
  1 42  2  0
 12 13  1  0
 42 43  1  0
 13 14  1  0
 43 44  2  0
 14 15  1  0
 44 45  1  0
 15 11  1  0
 45 46  2  0
 46  1  1  0
 12 10  1  1
 44 47  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)

Discover Target: CASP2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CASP3 Tchem Caspase-3 (3632 Activities)

Discover Target: CASP3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 659.74	Molecular Weight (Monoisotopic): 659.3166	AlogP: -0.31	#Rotatable Bonds: 13
Polar Surface Area: 220.54	Molecular Species: ACID	HBA: 9	HBD: 6
#RO5 Violations: 2	HBA (Lipinski): 15	HBD (Lipinski): 6	#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.26	CX Basic pKa: ┄	CX LogP: -0.15	CX LogD: -3.14
Aromatic Rings: 1	Heavy Atoms: 47	QED Weighted: 0.15	Np Likeness Score: 0.23

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C.. (2011) Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors., 19 (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors. 2006-03-09 Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors. 2011-10-01 Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors. [PMID:21903398]

(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3R)-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-lcarbamoyl)-3-p-tolyl-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source